With its main business focused on heparin and LMWH formulations,
Techdow is now a leading exporter of LMWH formulations in China.
Techdow's enoxaparin sodium injections are sold in China under the brand name Prolongin®, in the EU (except Poland) under the brand name Inhixa, in Poland under the brand name Neoparin, and in emerging markets under the brand name Prolongin/Inhixa and other local brands.
Techdow's heparin sodium injections are also sold in the U.S. market.
The first enoxaparin sodium biosimilar injection approved by the EMA of the EU
A leading exporter of LMWH formulations in China
The first generic enoxaparin sodium injection approved by China NMPA
One of the first few Chinese pharmaceutical companies with its own sales teams for formulated products in the EU market. To date, Techdow's enoxaparin sodium injections have recorded a total sales of approximately 480 million vials in the European market, making Techdow a market leader in the region.
Techdow's enoxaparin sodium injection (Prolongin®) is the first enoxaparin product selected by the 8th Centralized National Procurement in China
Techdow's enoxaparin sodium injections are sold in over 40 countries and regions around the world and are covered by the national medical insurance programs of the EU, UK, and Switzerland.
Trusted by doctors and patients for its batch-to-batch consistency, high purity, low rate of adverse events and excellent safety
A close-loop global heparin supply chain offering 100% traceability
Multiple world-class high-speed and fully-automated sterile injection production lines offering ample production capacity
A leader by market share in countries with high entry requirements, such as the UK, U.S., and EU, winning broad recognition and praise from customers in over 40 countries and regions across the world